Using 400 real-world patient cases, the CARE platform correctly classified 99.5 percent of cases according to NCCN guidelines ...

The EC granted conditional approval based on activity seen in a subset of IHC 3+ HER2-positive advanced biliary tract cancer patients in a Phase II trial.

The firm hopes that ETX-636's dual mechanism inhibiting mutant PI3Kα will give it an edge over competing products on the market.

The biotech has received written agreement from the agency through the START pilot program on key aspects of its trial design for evaluating NGN-401.